+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

FOSAMAX PLUS D Drug Profile, 2019

  • ID: 4727079
  • Report
  • February 2020
  • Region: Global
  • 132 pages
  • thinkBiotech LLC
1 of 4

FEATURED COMPANIES

  • Merck Sharp & Dohme Corp.
  • MORE
FOSAMAX PLUS D Drug Profile, 2019 is part of a deep library of business intelligence on biopharmaceutical drugs.

The report focuses on FOSAMAX PLUS D and covers the following critical aspects of this drug:
  • United States patents
  • Expired United States patents
  • FDA Paragraph IV patent challenges
  • District Court patent litigation
  • European supplementatry protection certificates (SPCs)
  • Clinical trials
  • Drug prices
  • Finished product suppliers
About the Researcher

The researcher is a provider of global business intelligence on biologic and small-molecule drugs, dedicated to helping clients make better decisions. Critical information on global drug patents is incorporated with litigation intelligence, drug prices, and historic sales figures to help users discover commercial opportunities and forecast future revenue events. Since 2005 the researcher has served hundreds of large and small companies in more than 65 countries.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Merck Sharp & Dohme Corp.
  • MORE
  • Profile for FOSAMAX PLUS D
  • US Patents
  • Expired US Patents
  • Paragraph IV Patent Challenges
  • US District Court Litigation
  • International (ex US) Patents
  • Supplementary Protection Certificates
  • Clinical Trials
  • Drug Prices - Average Pharmacy Cost
  • Drug Prices - Best Wholesale Price
  • Finished Product Suppliers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Merck Sharp & Dohme Corp.
Note: Product cover images may vary from those shown
Adroll
adroll